In a virtual media briefing next Tuesday, May 16, at 11:30 a.m. EDT, noted infectious disease expert Mark Rupp, M.D. will detail the results of a forthcoming journal publication on a new device.
The School of Oncoplastic Surgery (SOS), which zeroes in on the growing trend toward oncoplastic breast-conserving surgery, will hold its next training program Jan. 27-29, 2017.
Steven Schonholz, MD, FACS, will present a scientific poster on how BioZorb is used in the treatment of breast cancer at the 32nd Annual Miami Breast Cancer Conference, in Miami Beach, Fla., Feb. 26 to March 1.
The use of disinfection caps is included in major new infection-control recommendations sponsored by the Society for Healthcare Epidemiology of America (SHEA) and other top infection-control organizations.
There are substantial differences between the results provided by Agendia’s breast cancer genomic tests and more limited results from the 21-gene assay, according to findings presented at the recently concluded ASCO meeting.
A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer.
Jason Patric, the actor (best known for his roles in Lost Boys and Speed 2: Cruise Control) and activist, who is fighting to be an equal parent, will join three nationally known parenting experts in a virtual media conference Wednesday, June 4, the week leading up to Father’s Day.
New evidence showing that the MammaPrint® and BluePrint® tests provide insights into how to treat breast cancer was presented at the annual conference of the American Society of Breast Surgeons (ASBrS).
The BioZorb™ three-dimensional surgical marker improved the ability of radiation oncologists to target radiation treatment for breast cancer, according to a scientific presentation at the 2014 American Brachytherapy Society (ABS) Annual Meeting.
A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports.
Simply replacing the connector in the IV system in patients with central lines could help reduce deadly bloodstream infections, researchers at Georgia Regents University have found.
Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO).
Research on different types of IV connectors led a Johns Hopkins cancer center to pilot a “neutral pressure” IV connector, according to a scientific presentation at the annual meeting of the Oncology Nursing Society (ONS).
The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly published study.
Patients at NorthShore University HealthSystem are now better protected against potentially deadly infections, according to a newly published study.
A California hospital reported that its vascular access team has gone nearly seven years without a central line-associated bloodstream infection (CLABSI) in any of its peripherally inserted central catheter (PICC) lines.
The latest generation of genomic tests for breast cancer can improve physicians’ ability to diagnose the disease and more precisely tailor each patient’s treatment, according to a study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
The American Society of Breast Disease (ASBD) is merging art and medicine this week, by using clay sculpting and other techniques to teach surgeons new skills in breast cancer surgery and reconstruction.
Use of a simple disinfection cap can strengthen hospitals’ patient safety efforts, improve disinfection of IV catheters and lower the cost of care.
The type of IV connector used in vascular access is closely linked to a patient’s chance of getting a dangerous bloodstream infection, according to two new studies.
A new statement to help physicians inform women on how breast density affects breast cancer screening and cancer risk has been issued by the American Society of Breast Disease.
Breast brachytherapy with a strut-based applicator had favorable toxicity rates and cosmetic outcomes, according to research delivered at the American Society for Radiation Oncology (ASTRO).
RyMed Technologies will host a breakfast symposium on the origin of catheter-related bloodstream infections (CRBSIs) and how to prevent them at the upcoming Annual Scientific Meeting of the Association for Vascular Access (AVA).
IV connectors, through which intravenous medication and nutrition are provided to a patient, can play a crucial role in protecting patients from life-threatening infections and other complications.
A neutral-pressure IV needleless connector was associated with complete elimination of catheter-related bloodstream infections (CRBSI) in a successful device trial at a large cancer center in the six-month period following implementation of the device.
An IV connector known as an intraluminal protection device (IPD) outperformed a negative-pressure split septum IV connector, in a prospective clinical study that compared the occlusion rates of two IV connectors.
An IV connector known as an intraluminal protection device (IPD) significantly outperformed two widely used negative-pressure IV connectors in research performed at Methodist Extended Care Hospital.
A disinfection cap used in IV therapy was the subject of an award-winning, multi-site study at a four-hospital, Chicago-area hospital system.
Breast brachytherapy with a strut-based applicator is a well-tolerated and effective treatment for early-stage breast cancer, according to a multi-site study with a median follow-up of four years. The research was presented as a scientific poster at the European Society for Radiotherapy & Oncology (ESTRO) World Congress of Brachytherapy in Barcelona, May 10-12.
The American Society of Breast Disease (ASBD) is concerned about misleading information in a recent study published in the JAMA, comparing breast brachytherapy to whole breast irradiation.
Breast brachytherapy with a strut-based applicator appears to be an effective treatment for women who have ductal carcinoma in situ (DCIS) of the breast, according to a new study presented at the American Society of Breast Surgeons.
One of the leading experts on radiation therapy for breast cancer says a new study in JAMA -- about breast cancer treatment – has misleading information and may unnecessarily deter women from getting breast brachytherapy, a safe and effective treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right